Sarcopenia Cut-points and Functionality in Older Adults
NCT ID: NCT03832608
Last Updated: 2021-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2019-01-08
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preventive Physiotherapy Intervention in Elderly People With Sarcopenia
NCT02120586
Diagnostic Evaluation of Sarcopenia in Elderly Patients
NCT04451005
Sarcopenia and Aging
NCT00907010
Respiratory Sarcopenia in Institutionalized Older Adults in the Region of Murcia
NCT06130800
Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
NCT04717869
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main objective is to establish different cut-off points for the diagnostic criteria of sarcopenia and relate them with other instruments for assessing functionality in older population of Valencia Province.
To this purpose, data will be collected through various tests and questionnaires about: clinical, demographic and anthropometric characteristics; muscle mass; muscle strength; walk speed; physical and cognitive function; nutritional status; self-perception of health; comorbidity and frailty. With this information it will be possible, as primary outcome, to determine a more sensitive, reliable and valid muscle mass index to predict sarcopenia, and, as a secondary outcome, to establish the relationship between the multicriteria diagnostic of sarcopenia with the functional and frailty variables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Older adults and Sarcopenia
Older adults with and without Sarcopenia living in Valencia Province.
No intervention
There is not intervention to be administered, only collection of data through various tests and questionnaires.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
There is not intervention to be administered, only collection of data through various tests and questionnaires.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Residents in Valencia Province (Living-Community, Day-Centers and institutionalized)
Exclusion Criteria
* Any disorder that prevents from performing the assessment tests.
* Recent hospitalization or who are in a acute process of any illness (less one month).
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Valencia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maria dels Angels Cebria i Iranzo, PT, PhD
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria A Cebrià i Iranzo, PT, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Valencia
Mercè Balasch i Bernat, PT, PhD
Role: STUDY_CHAIR
University of Valencia
Anna Arnal Gómez, PT, PhD
Role: STUDY_CHAIR
University of Valencia
Trinidad Sentandreu Mañó, PT, PhD
Role: STUDY_CHAIR
University of Valencia
Maria A Tortosa Chuliá, PhD
Role: STUDY_CHAIR
University of Valencia
Natalia Cezón Serrano, PT
Role: STUDY_CHAIR
University of Valencia
Jose M Tomás, PhD
Role: STUDY_CHAIR
University of Valencia
Silvia Forcano Sanjuán, MD
Role: STUDY_CHAIR
Hospital Universitari i Politècnic La Fe (Valencia)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Armonea Group
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.
Masanes F, Culla A, Navarro-Gonzalez M, Navarro-Lopez M, Sacanella E, Torres B, Lopez-Soto A. Prevalence of sarcopenia in healthy community-dwelling elderly in an urban area of Barcelona (Spain). J Nutr Health Aging. 2012 Feb;16(2):184-7. doi: 10.1007/s12603-011-0108-3.
Salva A, Serra-Rexach JA, Artaza I, Formiga F, Rojano I Luque X, Cuesta F, Lopez-Soto A, Masanes F, Ruiz D, Cruz-Jentoft AJ. [Prevalence of sarcopenia in Spanish nursing homes: Comparison of the results of the ELLI study with other populations]. Rev Esp Geriatr Gerontol. 2016 Sep-Oct;51(5):260-4. doi: 10.1016/j.regg.2016.02.004. Epub 2016 Apr 9. Spanish.
Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JS, Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014 Feb;15(2):95-101. doi: 10.1016/j.jamda.2013.11.025.
Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK; ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc. 2013 Jul;14(7):528.e1-7. doi: 10.1016/j.jamda.2013.03.019. Epub 2013 May 10.
Ethgen O, Beaudart C, Buckinx F, Bruyere O, Reginster JY. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcif Tissue Int. 2017 Mar;100(3):229-234. doi: 10.1007/s00223-016-0220-9. Epub 2016 Dec 24.
Cebria I Iranzo MA, Arnal-Gomez A, Tortosa-Chulia MA, Balasch-Bernat M, Forcano S, Sentandreu-Mano T, Tomas JM, Cezon-Serrano N. Functional and Clinical Characteristics for Predicting Sarcopenia in Institutionalised Older Adults: Identifying Tools for Clinical Screening. Int J Environ Res Public Health. 2020 Jun 22;17(12):4483. doi: 10.3390/ijerph17124483.
Arnal-Gomez A, Cebria I Iranzo MA, Tomas JM, Tortosa-Chulia MA, Balasch-Bernat M, Sentandreu-Mano T, Forcano S, Cezon-Serrano N. Using the Updated EWGSOP2 Definition in Diagnosing Sarcopenia in Spanish Older Adults: Clinical Approach. J Clin Med. 2021 Mar 2;10(5):1018. doi: 10.3390/jcm10051018.
Balasch-Bernat M, Sentandreu-Mano T, Tomas JM, Cebria I Iranzo MA, Tortosa-Chulia MA, Arnal-Gomez A, Cezon-Serrano N. Deepening the understanding of the structural validity of the Tilburg Frailty Indicator. Aging Clin Exp Res. 2023 Jun;35(6):1263-1271. doi: 10.1007/s40520-023-02407-w. Epub 2023 Apr 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H1542733812827
Identifier Type: OTHER
Identifier Source: secondary_id
H1542733812827
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.